BGB-58067

DRUG2 trials

Sponsors

BeOne Medicines, Nader Sanai

Conditions

Advanced Solid TumorGlioblastoma (GBM)

Early Phase 1

Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

Not yet recruitingNCT07485049

Nader SanaiGlioblastoma (GBM)

Start: 2026-04-01End: 2028-04-01Target: 78Updated: 2026-03-20

Phase 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

RecruitingNCT06589596

BeOne MedicinesAdvanced Solid Tumor

Start: 2024-10-11End: 2029-01-01Target: 244Updated: 2026-03-19

Related Papers

Abstract CT193: Trial in progress: A first-in-human phase 1a/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency

Cancer Research2025-04-251 citations